We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
23 Jan 2021 - 27 Jan 2021
Virtual Venue
24 Feb 2021 - 28 Feb 2021
Virtual Venue

Blood Biomarker Predicts Guillain-Barré Prognosis

By LabMedica International staff writers
Posted on 25 Nov 2020
Print article
Image: Histopathology of Guillain-Barré syndrome: Inflammation in peripheral nerve (Photo courtesy of Dimitri P. Agamanolis, MD).
Image: Histopathology of Guillain-Barré syndrome: Inflammation in peripheral nerve (Photo courtesy of Dimitri P. Agamanolis, MD).
Guillain-Barré syndrome (GBS) is a rare, autoimmune disorder in which a person’s own immune system damages the nerves, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage.

The diagnosis of GBS depends on findings such as rapid development of muscle paralysis, absent reflexes, absence of fever, and absence of a likely cause. Cerebrospinal fluid analysis (through a lumbar spinal puncture) and nerve conduction studies are supportive investigations commonly performed in the diagnosis of GBS. Testing for antiganglioside antibodies is often performed, but their contribution to diagnosis is usually limited.
Gold Supplier
COVID-19 Antibody Rapid Detection Kit
COVID-19 Antibody Rapid Detection Kit
COVID-19 Anitibody Test
SGTi-flex COVID-19 IgM/IgG
Visit expo >

A team of neurologists and their colleagues associated with the Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) measured serum neurofilament light chain (sNfL) in 98 samples and 24 cerebrospinal fluid (CSF) samples of GBS patients using single-molecule array technology, comparing them with samples from 53 age-matched healthy controls.

GBS patients were an average age of 57, and 57.1% were men. Most (68.4%) presented with GBS symptoms after an infectious event; median time from symptom onset to inclusion in the study was four days. Two-thirds of patients presented with the typical sensorimotor variant of GBS. Most patients were treated with intravenous immunoglobulin (77.6%) or intravenous immunoglobulin plus plasma exchange (10.2%).

The scientists reported that at baseline, median sNfL levels were five times higher for GBS patients than controls (55.49 pg/mL versus 9.83 pg/mL) and CSF levels were also higher (1,308.5 pg/mL versus 440.24 pg/mL). GBS patients with preceding diarrhea had higher sNfL levels than patients with respiratory symptoms or those who had no preceding infection (134.90 pg/mL versus 47.86 pg/mL versus 38.02 pg/mL), respectively. Patients with pure motor GBS variant and Miller Fisher syndrome showed higher sNfL levels than patients with typical GBS (162.18 pg/mL versus 95.50 pg/mL versus 38.02 pg/mL). Patients with acute motor axonal neuropathy (AMAN) had higher serum sNfL levels than other variants (199.53 pg/mL versus 46.77 pg/mL).

Luis Querol, MD, PhD, a Neurologist and co-author of the study, said, “These findings are important on several levels. First, they confirm that residual long-term disability in GBS is clearly associated to the degree of axonal damage that happens at the onset of the disease. They also suggest that sNfL could be used to stratify patients at admission, and in the future, select patients who may be candidates for more aggressive therapies or those who may have good prognosis independently of the apparent severity they have at onset.”

The authors concluded that baseline sNfL levels are increased in patients with GBS, are associated with disease severity and axonal variants and have an independent prognostic value in patients with GBS. The study was published on November 5, 2020 in the Journal of Neurology, Neurosurgery, and Psychiatry.

Related Links:
Hospital de la Santa Creu i Sant Pau

Print article


Molecular Diagnostics

view channel
Image: Histopathology of neurofibrillary tangles in the brain of a patient with Alzheimer`s disease (Bielschowski silver stain) (Photo courtesy of Dimitri P. Agamanolis, MD).

Alzheimer's Disease Subtypes Proposed from Brain Gene Expression Profiles

Alzheimer’s disease (AD) is the most common form of dementia in the elderly, estimated to affect more than 5.8 million individuals in the USA and more than 50 million worldwide, with almost half of individuals... Read more


view channel

Thermo Fisher Acquires Point-of-Care Molecular Diagnostics Provider Mesa Biotech

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has entered into a definitive agreement to acquire Mesa Biotech (San Diego, CA, USA), a privately held molecular diagnostic company, for approximately USD... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.